USA – Impending merger or acquisition?
William Strange, Milliman | 4 March 2019
The health of employee benefit programs can be a make-or-break issue
The day after biotech firm Bristol-Myers Squibb (BMS) announced a proposed acquisition of pharma company Celgene, news headlines focused on the particulars of the deal, and the potential for the first big acquisition of 2019 to be a catalyst for biotech takeovers in the coming year. The BMS news certainly started the new year off with a bang, continuing a trend from 2018 in which merger and acquisition (M&A) activity was high, with worldwide deals valued at nearly $4 trillion according to the Institute for Mergers, Acquisitions and Alliances (IMAA).